leisure time -WSS

leisure time

author：explore 2025-09-30 11:57:38 - browse：81448

Allergan, Dom Smith/STAT

It wasn’t supposed to work out this way for Brent Saunders.

Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Creating egg and sperm cells from stem cells raises ethical issues

hotspot

WSS

Positive childhood experiences can help future health

#NeedHerScience: shining a light on gender disparities in medicine

Gene therapy has helped boys walk. Can scientists keep it that way?

Gene editing the human germline: What are the risks?

Weight bias in eating disorder treatment complicated by new weight loss drugs

Argenx readies a blockbuster opportunity with drug for autoimmune disease

knowledge

leisure time

explore

After affirmative action ruling, medical educators look to 'holistic review'

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

The cancer drug shortage isn’t new — and neither are the solutions

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Medicare details structure of new drug price negotiation program

Creating egg and sperm cells from stem cells raises ethical issues

Activists slam private health insurers over coverage restrictions

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

FDA approval of Sarepta Duchenne genetic therapy gives me hope

App could help diagnose ear infections more accurately — and at home

hotspot

U.K. researchers warn about biases in medical devices, algorithms

Stop the failed accountable care organization experiment

3 hurdles to bringing medical devices to the U.S. market

Neuroscience’s long legacy of racism

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Wikipedia

hotspot

hotspot

hotspot